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Abstract 
Oxidative stress has been implicated in the pathophysiology of diabetic nephropathy. Studies in 
experimental animal models of diabetes strongly implicate oxidant species as a major determinant in 
the pathophysiology of diabetic kidney disease. 
The translation, in the clinical setting, of these concepts have been quite disappointing, and new 
theories have challenged the concepts that oxidative stress per se plays a role in the 
pathophysiology of diabetic kidney disease. 
The concept of mitochondrial hormesis has been introduced to explain this apparent disconnect. 
Hormesis is intended as any cellular process that exhibits a biphasic response to exposure to 
increasing amounts of a substance or condition: specifically, in diabetic kidney disease, oxidant 
species may represent, at determined concentration, an essential and potentially protective factor. 
It could be postulated that excessive production or inhibition of oxidant species formation might 
result in an adverse phenotype. 
This review discusses the evidence underlying these two apparent contradicting concepts, with the 
aim to propose and speculate on potential mechanisms underlying the role of oxidant species in the 
pathophysiology of diabetic nephropathy and possibly open future more efficient therapies to be 
tested in the clinical settings. 
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Graphical abstract 
Mitochondrial hormesis could represent an important concept that could allow us to dissect the 
hazardous vs beneficial role of reactive oxygen species levels in the pathophysiology of diabetic 
nephropathy. 
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Introduction 
Diabetes Mellitus 
Diabetes mellitus (DM) is a metabolic syndrome, characterised by chronic hyperglycaemia and 
glucose intolerance because of defects in insulin action or secretion, or a combination of both [1]. 
The worldwide burden of diabetes is rapidly rising, with a dramatic increase in prevalence in 
recent decades [2, 3]. Estimated figures from the International Diabetes Federation predicted that 
422 million people were living with diabetes in 2014, and these figures are expected to increase to 
642 million by 2040 [4](http://www.diabetesatlas.org). This translates into the reality that a 
shocking one out of ten people will have diabetes in 20 years. At present, China has been reported 
to have the greatest incidence of DM, affecting 94.8 million of the population, followed closely by 
India and the USA [5]. 
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Diabetes is the 5th leading cause of morbidity and mortality worldwide [6]. The significant global 
impact of this condition is acknowledged internationally, with diabetes ranking highly on the 
international health agenda [7]. With 5% of the UK population affected by this condition, diabetes 
has become a major challenge in 21st century healthcare [8, 9]. This is largely due to the associated 
micro and macro-vascular complications of diabetes, affecting diabetic populations in both 
developed and developing countries [7, 9]. The microvascular complications include diabetic 
nephropathy, retinopathy and neuropathy, and are responsible for significant morbidity [10]. The 
diabetic macro-vascular complications represent the most common cause of mortality in patients 
with diabetes; these include accelerated coronary heart disease, ischemic stroke and peripheral 
vascular disease [11]. 
 
Classification of Diabetes Mellitus 
The American Diabetes Association classification of DM is currently the most widely used 
classification system for diabetes in clinical practice [12]. Classification of DM is largely based on 
aetiology and not pharmacologic treatment, largely due to an improved understanding of the 
causes underlying diabetes. The two major forms of diabetes are type 1 diabetes mellitus (T1DM), 
an auto-immune disorder characterised by the destruction of the insulin producing β-cells in the 
islets of Langerhans which accounts for 5-10% of cases, and type 2 diabetes mellitus (T2DM), a 
more common form of DM which accounts for up to 90% of cases and is due to impaired insulin 
secretion and/or insulin action, as a result of insulin resistance [12]. With the increasing global 
incidence of obesity, T2DM now typically affects a younger and more obese patient group [7]. 
 
Diabetic Nephropathy 
Classification of Diabetic Nephropathy 
Diabetic nephropathy (DN), a serious and most feared microvascular complication of diabetes, is a 
chronic progressive disease of the kidney, characterised by persistent albuminuria and progressive 
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relentless decline in glomerular filtration rate (GFR). Diabetes leads to disruption of the renal 
microvasculature, with progressive damage at the level of the glomerular capillaries and tubular 
interstitium [13]. Traditionally, DN has five identified stages based on GFR and urinary albumin 
excretion (UAE): glomerular hyperfiltration, a silent stage, incipient nephropathy with 
microalbuminuria, overt nephropathy and, finally, end stage renal disease (ESRD)(Table 1)[14]. 
Diabetic nephropathy is currently the leading cause of ESRD in the western world. Consequently, 
diabetes is a principal cause for patients requiring renal replacement therapy, with diabetic 
patients contributing to approximately 45% of the individuals on renal replacement therapy 
worldwide [15]. 
 
Epidemiology of Diabetic Nephropathy 
The incidence of DN has substantiality increased over recent years, although recent data from the 
United States Renal Data System (USRDS) suggests that incidence counts for ESRD are beginning to 
plateau, whilst prevalence counts are rising [16]. DN develops over time, with a peak incidence 
after 10-20 years duration of diabetes and affects a striking 45% of diabetics, with a similar 
incidence in both T1DM and T2DM patients [13]. In some patients the diabetes-driven renal 
damage is so minimal that it remains clinically silent during their entire lifetime [17]. Importantly, 
following 5 years of consistent proteinuria, the cumulative risk of developing ESRD in both T1DM 
and T2DM stands an estimate of 60% [18]. Ethnicity can influence the severity and incidence of 
DN, as DN is more prevalent in African Americans, Asians and Native Americans, compared to 
White Caucasians populations [19]. 
 
Cardiovascular-Renal Complications of Diabetic Nephropathy 
Diabetes increases the risk of developing cardiovascular disease (CVD) by two-fold compared to 
the non-diabetic general population. The incidence of myocardial infarction in the diabetic 
population is increased by three-fold compared with the general population and DN considerably 
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adds to this observed increase of cardiovascular morbidity and mortality [20, 21]. Furthermore, 
DN is also a major risk factor for CVD, which is currently the leading cause of death in both T1DM 
and T2DM worldwide [22-24]. In the diabetic population, CVD accounts for more than half of 
deaths [25]. A large majority of patients with DN will die even before progression to ESRD as a 
result of CVD related causes [26]; importantly DN is associated with an increase in myocardial 
infarction and cerebrovascular events [27]. The significant healthcare burden due to the epidemic 
of DN, on both the individual and the healthcare system, is of major concern and requires 
attention to achieve a suitable and effective solution. A better understanding of the 
pathophysiology underlying DN is crucial to direct methods for early intervention and novel 
treatments to prevent the progression and reduce cardiovascular morbidity and mortality in the 
future. 
 
Oxidative stress in the pathogenesis of diabetic nephropathy 
Oxidant species are products of normal oxygen metabolism and are important in processes such 
as cell signalling, ageing and degenerative disease [28]. In health, an intricate balance exists 
between oxidant species, recognised important signalling molecules for normal cell physiology 
[29] and anti-oxidant activity to prevent potential damaging effects secondary to excess oxidant 
species tissue accumulation. Importantly, factors that lead to an imbalance in the oxidant species 
/anti-oxidant equilibrium, either in the form of increased oxidant species production or diminished 
anti-oxidant activity, can lead to excess oxidative stress and subsequent tissue injury [28]. 
Numerous pathophysiological mechanisms underlying DN have been described, in which 
increased oxidant species have been identified as the single unifying upstream event [30]. Thus, 
increased oxidant species holds a central and prominent role in the pathophysiology of diabetic 
microvascular complications, and for this discussion, DN. 
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In vitro and in vivo experimental models of diabetes have established that metabolic 
(hyperglycaemia, dyslipidaemia)[31] and haemodynamic (systemic and glomerular hypertension) 
[17] insults represent the two major drivers of oxidative stress in the diabetic kidney. 
The kidney is particularly vulnerable to damage caused by elevated circulating glucose levels. The 
nephron (glomeruli and tubuli) is an insulin independent organ and the flux of glucose into the 
cells is regulated by the ambient circulating glucose levels and the expression of facilitative 
glucose transporters (GLUT1)[17]. 
Indeed, the interaction between metabolic (hyperglycaemia) and haemodynamic (hypertension) 
perturbations, and their secondary modulation of different intercellular signalling pathways, 
appears to be key and represents an important driver of DN (Fig. 1). Hyperglycaemia-mediated 
increase in vascular nitric oxide [32] and transforming growth factor (TGF)-β1 [33, 34] through the 
production of oxidant species [35], have been linked to vasodilation of both afferent and efferent 
glomerular arteriolae. Hyperglycaemia also activates the local tissue renin-angiotensin-
aldosterone system (RAAS): a concept first proposed by Hostetter [17, 36] whereby local 
(glomerular) dysregulation of the RAAS results in local excess production of angiotensin II. In 
diabetes, the documented higher sensitivity of the efferent (versus the afferent) glomerular 
arteriole to the vasoconstrictive action of angiotensin II, contributes to the imbalance in arteriolar 
tone which then results in higher glomerular capillary pressure [17, 37]. As a result, in diabetes, a 
disproportionate systemic pressure is transmitted to the glomerular circulation resulting in 
glomerular cell mechanical elongation and activation of the cellular mechanisms that lead to 
glomerular damage [38]. 
The haemodynamic perturbations have been proposed as a potential mechanism for upregulation 
of the facilitative glucose transporter GLUT1 in mesangial cells, resulting in increased glucose flux 
into the cells and secondary cell damage [39]. An excess in cellular glucose transport due to 
metabolic-haemodynamic interaction, synergistically fuels an increase in oxidant species 
production and the manifestations of DN and other diabetic microvascular diseases [40]. 
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The Glomerular Filtration Barrier (GFB) 
DN causes unique ultra-structural alterations in the nephrons of the kidney, at the level of the 
glomerulus. The GFB is a complex structure, composed of three key components; specialised 
epithelial cells known as podocytes, highly fenestrated glomerular endothelial cells and the 
glomerular basement membrane (GBM), a thin membrane separating these two groups of cells. In 
health, this structure plays an important role in maintaining the permselective function of the 
glomerulus. The distinct ultrastructure of glomerular endothelial cells, which lack fenestra 
diaphragms between the fenestrations and are covered by a glycocalyx, facilitates the filtration of 
water and small solutes and regulates the permeability of the glomerulus in physiology [41, 42]. 
Albuminuria is a direct result of defects at the level of the GFB [41] and is one of the earliest signs 
of DN. The degree of albuminuria can correlate with and is also an important clinical predictor of 
the rate of progression towards ESRD [43, 44]. Moreover, according to the Steno hypothesis, the 
presence of increasing albuminuria is indicative of widespread systemic vascular damage [45]. 
Therefore, understanding the normal structure, function and physiology of the glomerulus and the 
GFB and the changes that occur in DN is crucial. Hallmark pathological changes that occur in DN at 
the glomerulus include diffuse mesangial expansion and sclerosis, alteration of the endothelial 
glycocalyx, GBM thickening, podocyte foot process effacement and detachment and a reduction in 
podocyte number [46](Fig. 2). 
 
Mesangial Cells in DN 
Mesangial cells hold the glomerular capillaries and form the glomerular tuft (Fig. 2). In diabetes, 
progressive deposition of extracellular matrix sclerosis affects the glomerular tuft initially. In 
humans, progressive mesangial expansion has been proposed as the main mechanism for loss of 
kidney function [47]. This progressive extracellular matrix deposition and accumulation results in 
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the formation of nodules, first described by Kimmelstiel and Wilson, that with progressive matrix 
deposition lead to capillary obliteration and progressive and diffuse glomerulosclerosis [48]. 
 
Glomerular endothelial cells in DN 
The endothelium plays a central role in the pathophysiology of diabetic glomerulopathy. 
Endothelial dysfunction precedes glomerular permeability to albumin [49, 50], and has been 
suggested as the initial pathogenic mechanism for chronic vascular diabetic complications [45, 51]. 
Diabetes drives glomerular endothelial cell injury by causing loss of glycocalyx and promoting cell 
apoptosis [52]. The glycocalyx is composed of heparan sulphates, hyaluronic acid, sialoprotein, 
and proteoglycans [53, 54], and forms a fluid extracellular layer that covers the glomerular 
capillary lumen; changes in the glycocalyx results in alteration of glomerular endothelial cell 
function and alteration in vascular permeability [41, 52]. 
 
Podocytes in DN 
Podocytes are terminally differentiated glomerular cells with distinct interdigitating primary and 
secondary foot processes, which are linked to form slit diaphragms [55]. These slit diaphragms are 
specialised size-selective barriers composed of nephrin, neph1 and podocin proteins which tightly 
regulate the size of molecules in the glomerular filtrate, preventing the filtration of 
macromolecules [56, 57]. Nephrin also has an associated role in the maintenance of normal 
podocyte actin cytoskeleton structure and function through interactions with signalling proteins 
and cascades, namely phosphoinositide 3-kinase (PI3K), PI3K-dependant Protein kinase B (AKT) 
phosphorylation and, subsequent, increased Ras-related C3 botulinum toxin substrate-1 (Rac1) 
activity [58]. In health, podocytes are crucial in preserving the integrity of the glomerular 
capillaries, regulating the synthesis of extracellular matrix proteins and maintaining the 
permselectivity of the GFB [59]. 
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In diabetic environments, the structure and function of podocytes are disrupted, leading to excess 
extracellular matrix deposition, subsequent GBM thickening and foot process fusion and 
detachment from the GBM [60]. Research has suggested that podocyte damage is often the 
trigger of the cascade that results in major structural and functional disruptions of the glomerular 
capillaries in glomerular disease [61]. Evidence from studies looking at the early glomerular 
alterations in experimental animal models of T2DM in ZDF-fa/fa rats and Goto Kakizaki rats have 
shown podocyte injury present without mesangial expansion, suggesting the podocytes are the 
initial trigger in diabetes-induced glomerular disease [62]. 
Experimental animal models of diabetes have demonstrated that podocyte loss is followed by foot 
process widening in remaining podocytes, which is believed to be a compensatory mechanism in 
order to cover the exposed GBM surface area as podocytes lack regenerative capacity and cannot 
be replaced [63]. This largely results in proteinuria and at a later stage, progressive 
glomerulosclerosis. 
 
Oxidative stress in the glomerulus 
In the glomerular capillaries, oxidant species-mediated damage affects all the layers of the 
glomerular filtration barrier, beginning with functional alterations of the interaction between 
glomerular endothelial cells with their glycocalyx layer and podocytes [64], followed by 
extracellular matrix deposition mainly characterised by an increased expression/secretion of type-
IV collagen [65]. 
Importantly, the endothelial cells glycocalyx, mainly composed by proteoglycans and 
glycosaminoglycans enriched in heparan sulphate, recognised as a crucial component of the 
glomerular filtration barrier [66, 67], is a major target for oxidant species. Excess hydrogen 
peroxide favours shedding of heparan sulphate from glycosaminoglycans and/or 
glycosaminoglycans degradation, secondary decrease in anionic charges and increase in 
glomerular permeability to macromolecules [68, 69]. Oxidant and nitrogen species-mediated 
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activation of matrix metalloproteinases and inhibition of endogenous protease inhibitors has also 
been proposed as a potential mechanism for glycocalyx degradation [70, 71]. 
Similarly, the GBM, known to retain charge properties for the anionic heparan sulphate side chains 
attached to the core proteins agrin and perlecan, and the fine extracellular matrix network 
structure, crucial in maintaining its permselective properties [72], can be targets of excess oxidant 
species production. Hydroxyl radical and other oxidant species have been implicated in the 
depolymerisation of heparan sulphate and proteoglycan core proteins [73, 74] and simultaneously 
affect protein degradation and cross-linking of type-IV collagen [75], closely involved in the 
maintenance of the permselective properties of the GBM.  
Experimental models of diabetes have demonstrated that elevated circulating levels of glucose 
and free fatty acids can both be potent activators of NADPH oxidase [76-81]. Further metabolic-
mediated increased activation of the RAAS [15] has been recognised as one of the major activators 
of NADPH oxidase and oxidant species formation [82, 83]. 
A potent and principle role of NADPH oxidase enzymes in the production of vascular and renal 
oxidant species has been thoroughly documented in the diabetic kidney [40, 84]. The strong 
association between NADPH-mediated superoxide anion and hydrogen peroxide production and 
diabetic nephropathy pathogenesis is evident, with numerous experimental studies reporting 
enhanced expression of NADPH oxidase subunits in the diabetic renal compartment [80, 85-91]. 
Of interest and extensive scientific investigation in recent years is the Nox4 subtype, which has 
been identified as the key source of renal oxidant species driving diabetic nephropathy [91, 92]. 
Inhibition of Nox4 activity results in decreased oxidative stress and renal tissue damage in 
experimental models of diabetic nephropathy [78, 93]. Gorin et al. reported attenuation of renal 
hypertrophy and mesangial expansion following treatment with Nox4 antisense oligonucleotides 
in streptozotocin-induced diabetic rats [91]. The renoprotective effects of targeting Nox4 have 
also been demonstrated in a study by Jha et al. in which Nox4 knock-out was associated with 
prevention of glomerular damage in streptozotocin-induced diabetic mice [78]. 
 11 
Nox1 and Nox2 are also believed to be important players in the pathogenesis of diabetic 
nephropathy [77]. The overexpression of Nox2 in the kidneys of diabetic mice has been described 
in a study by Fukuda et al.; in this study, treatment with either angiotensin receptor blockers or 
ppar-y agonists resulted in inhibition of Nox2 overexpression and a parallel reduction in oxidative 
stress and renal fibrosis [94]. These findings are consistent with the work of Oudit et al. where 
treatment with human recombinant angiotensin converting enzyme-2 resulted in Nox2 
downregulation and reduction of kidney injury in Akita diabetic mice [95]. A recent study by 
Nagasu et al. demonstrated an association between increased endothelial Nox2 activity in 
transgenic diabetic Akita mice and renal injury [77]. 
Nox2 expression and superoxide production from macrophages [96] has been implicated in DN as 
advanced oxidation protein products promote inflammation and Nox2 upregulation has been 
observed in experimental animal model of diabetes [90]. The role of Nox2 in DN is still to be 
defined as studies in Nox2 deficient mice did not demonstrate a role for Nox2 in DN as 
observations were confounded by a parallel Nox4 upregulation [88]. Of note, Nox2 inhibition 
appears an inappropriate target in DN because of the increased susceptibility to infections seen in 
Nox2-deficient animals [97]. 
Dual pharmacological inhibition of Nox4 and Nox1 has been shown to successfully reduce 
oxidative stress and subsequently, renal fibrosis and albuminuria in recent studies of diabetic mice 
models [93, 98]. However, a recent study suggests pan-inhibition of Nox1, Nox2 and Nox4 
provides improved renoprotection in db/db mice compared to dual Nox1/Nox4 inhibitors [99]. 
Consequently, the Nox family poses a promising therapeutic target in the amelioration of 
oxidative stress for the prevention and treatment of diabetic nephropathy. 
Podocytes are very susceptible to oxidant species-mediated damage. Hyperglycaemia-induced 
oxidant species results in podocyte dysfunction/damage following the activation of several 
pathophysiological events such as apoptosis, cell detachment from GBM, podocyte foot process 
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fusion/effacement, cytoskeleton alterations and reorganisation, and dysregulation of crucial 
podocyte proteins involved in the regulation of glomerular capillaries permeability. 
Different mechanisms have been implicated in podocyte apoptosis [100, 101] in diabetes: 
autophagy, alteration in cell cycle and proliferation, cell death secondary to alteration in cell-
matrix interaction, necrosis and cell-in cell death. Both activation of NADPH oxidase and 
mitochondrial oxidant species generation have been identified as activators, in podocyte, of pro-
apoptotic pathways (p38MAPK and caspase-3) in experimental animal models of diabetes [100, 
102, 103]. Increased diabetes-mediated secretion of TGF1 has been implicated in podocyte 
apoptosis via SMAD-7/p38MAPK/caspase-3 activation [104] or Blc2-associated X protein (Bax) 
expression/translocation in the mitochondria, which in turn results in cytochrome-c release from 
mitochondria and activation of caspase-3 [100, 104, 105]. Hydrogen peroxide-mediated increase 
in TGF1 expression [89, 106] has been found to fuel NADPH oxidase activation [107] and 
increases in mitochondria oxidant species production [108], which contribute towards an increase 
in cellular oxidative stress and secondary apoptosis. Furthermore, increased expression of 
antioxidant enzymes in transgenic diabetic mice has demonstrated protective properties against 
diabetes-mediated oxidative stress and parallel podocyte protection in early phases of diabetic 
nephropathy [109]. 
Oxidant species have been implicated in podocyte detachment/apoptosis via downregulation of 
31 integrin [110-112], one of the most important podocyte anchoring receptors on the GBM 
[113]. Podocytes are indeed found in the urine of patients with diabetes and represent a marker 
of renal disease progression [114]. 
Oxidative stress activates [115, 116] Rho-GTPases, which in turn have been linked to podocyte 
dysfunction, specifically in processes involving cytoskeleton rearrangement and foot process 
effacement [117]. 
Diabetes-mediated changes to the mitochondria and the closely connected endoplasmic reticulum 
(ER)[118] play an important role in diabetic glomerulopathy. As discussed, the mitochondrial 
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metabolic overload and resulting increased cellular oxidative stress results in ER-stress which leads 
to the activation of unfolded protein response (UPR)[119]. UPR is a positive cellular response that 
in its early phase either refolds accumulated unfolded proteins, or degrades unfolded protein by 
the ubiquitin-proteasome pathway. However, when the unfolded protein and cellular damage 
exceeds a threshold, chronic and unresolved stress results in a change from an adaptive to pro-
apoptotic responses [119]. 
There is evidence that oxidative stress-mediated ER stress could play a role in diabetic kidney 
disease [120]. Indeed, hyperglycaemia and the subsequent increased glycation of proteins have 
been shown to mediate apoptosis partly through increases in ER stress in murine podocytes 
cultured in vitro [121, 122]. 
Adenosine monophosphate-activated protein kinase (AMPK) is a stress-activated kinase that acts 
to preserve cell survival under conditions of reduced substrate utilisation. AMPK activation 
promotes mitochondrial substrate utilisation and ATP generation, in parallel with stimulation of 
antioxidant gene expression to ensure an optimal redox balance [123]. In diabetes, AMPK is 
downregulated in the kidney and associated with impaired mitochondrial function [124] and 
reduced AMPK-mediated inhibition of NADPH oxidase (Nox2) resulting in increased oxidant 
species production [85, 125]; upregulation/activation of AMPK has been proposed as a potential 
therapeutic intervention in the diabetic kidney [126]. 
As mentioned above, oxidative stress mediates extracellular matrix production in the glomeruli. 
This has been demonstrated in experimental models of glomerular hypertension (Dahl salt 
sensitive rats)[127], in young spontaneously hypertensive rats [128] and in experimental mouse 
model of diabetes [129]. Elevated levels of oxidant species stimulate fibronectin mRNA expression, 
protein synthesis via PKC activation and activation of the transcription factors NFkβ and activator 
protein-1 (AP-1) both in experimental animal models [130] and in human diabetic glomeruli [131]. 
Upregulation of heme oxygenase 1 (HO-1), one of the major antioxidant response proteins, has 
been implicated as a cytoprotective mechanism in the kidney [132-134]; fibronectin expression is 
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increased in glomeruli of HO-1 deficient animals [135], and bilirubin, a product of the HO-1 
metabolism of heme, is known to attenuate TGFβ1-mediated fibronectin expression [136]. 
Furthermore, Nrf2, a potent transcription factor regulating antioxidant response [137], has been 
found to act as a transcriptional repressor of TGFβ1, both in vivo and in vitro, by interacting with 
the transcription factors c-Jun and SP1 and inhibiting their pro-TGFβ1 effects [80]. A recent report 
suggested that TGFβ1 may not be necessary for extracellular matrix deposition in patients with 
diabetic nephropathy [138], and studies have proposed a superoxide-activated ERK-dependent 
extracellular matrix gene transcription in mesangial cells [139], implicating more of a direct effect 
of Nrf2/HO-1 axis on fibrosis. 
Sulforaphane, an activator of Nrf2, promotes amelioration of diabetic nephropathy in animals 
through decreased expression of TGF-β1 and connective tissue growth factor (CTGF) [140, 141]. 
Other Nrf2 activators have also shown a clear protective role in experimental animal models of 
diabetic kidney disease [142, 143]. 
The increased oxidant species production in the glomerular microcirculation [144] results in the 
reduced availability of nitric oxide (due to eNOS uncoupling), resulting in oxidative stress-
mediated inflammation, endothelial dysfunction and podocyte detachment from the glomerular 
capillaries with increased glomerular permeability [15]. 
In experimental models of type 2 diabetic nephropathy, overexpression of CuZnSOC, a variant of 
the antioxidant superoxide dismutase enzyme, protects against end organ damage [145]. 
Furthermore, polymorphisms in manganese-superoxide dismutase, an additional enzyme subtype, 
are associated with the development of diabetic nephropathy in patients with T1DM [146], 
supporting an important role of oxidative stress in diabetic kidney disease. 
 
Tubular Compartment in DN 
Although the glomerulus has a well-defined role in the pathogenesis of diabetic nephropathy, the 
tubular compartment is highly affected by diabetes [147]. The tubular interstitial compartment 
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constitutes up to 90% of renal volume and is composed of the renal tubules, interstitial cells and 
the renal microvasculature. One third of patients with diabetic nephropathy have minimal 
glomerular alterations, however marked lesions affecting the tubule-interstitial compartment are 
present in this patients’ group [148]. A stronger correlation between the progression of 
nephropathy and tubular-interstitial alterations, as compared to glomerular alterations, is widely 
recognised [148, 149]. 
Tubular proteinuria is an early marker of DN and precedes microalbuminuria at the glomerulus 
[150]. Tubular hypertrophy and thickening of the tubular basement membrane are early 
histological changes associated with diabetic nephropathy. With advanced disease, this manifests 
with tubular atrophy and tubulointerstitial fibrosis [151]. 
 
Oxidative stress in the tubular compartment 
Hyperglycaemia affects the tubular structures directly from the tubular cell base-lateral side and, 
in parallel, the increase in glucose filtration results in an elevated tubular glucose load and 
exposure. Of interest, diabetes is paralleled by an upregulation of the Na+ coupled energy 
dependent glucose transporter SGLT2 (localized in the proximal tubuli)[152, 153], the major player 
in glucose reabsorption in the nephron [154]. The upregulation of SGLT2 and secondary increase 
in glucose proximal tubule reabsorption results in the activation of the local angiotensin II system 
and growth factors (e.g. CTGF, TGFβ1) resulting in tubular hypertrophy, increased oxidative stress, 
tubular cells apoptosis, inflammatory infiltrates, oxidative stress and increased extracellular matrix 
deposition [155-158]. 
In physiology, the kidneys receive approximately 25% of cardiac output which potentially could 
deliver 84 mL/min/100 g tissue of oxygen; of importance, renal oxygen consumption is close to 
6.8 mL/min/100 g [159]. Arterial-to-venous (AV) oxygen shunting occurs in the kidneys as a 
protection against hyperoxia-induced reactive oxygen superoxide production [160-162]. 
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Conversely, diabetic kidneys are susceptible to hypoxia: hyperglycaemia-induced hyperfiltration 
and the increase in renal blood flow, paralleled by increased oxygen consumption, result in an 
enhanced arterio-venous oxygen gradient which in turns leads to an increased arterio-venous 
oxygen shunting and hypoxia [160, 163]. 
In physiology, the transcription factor hypoxia-inducible factor (HIF-1α) mediates cell adaptation 
to hypoxia in the renal tubuli by stimulating vasculogenesis and protecting against fibrotic 
processes through the inhibition of connective tissue growth factor [164, 165]. The diabetic 
hypoxic kidney is characterised by a lack of compensatory activation of HIF-1α as hyperglycaemia 
per se promotes HIF-1α protease degradation [166, 167] and via excess of oxidant species 
production which has been implicated in HIF-1α destabilization; this is paralleled by progressive 
inflammatory responses and tubulointerstitial fibrosis [168]. 
 
Sources of Oxidative Stress in Diabetes (Fig.3) 
Many sources of oxidative stress have been described and implicated in diabetic kidney disease. 
Nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase: 
NADPH oxidase is formed by the interaction of different enzymes that transport electrons across 
the cell membrane, reducing oxygen to superoxide. Of these enzymes, the major identified 
transmembrane subunits are Nox1, Nox2 (gp91phox), Nox3, Nox4, Nox5, and two dual oxidases, 
Duox1 and Duox2. The catalytic subunits of Nox1-4 depend on the membrane bound p22phox 
subunit, while the others are independent of p22phox. 
Upon stimulation, specific combinations of cytosolic subunits p47phox, p67phox, p40phox, and 
GTPase Rac1 or Rac2, form a complex that associates with the membrane subunits to form an 
active NADPH oxidase multi-subunit complex and promote the generation of superoxide [169]. 
In the kidney, NADPH oxidase has been identified in both the glomerulus (in mesangial cells, 
endothelial cells and podocytes) and in the tubular compartment [170-176]. Specifically, Nox1, 
Nox4, p22phox, p47phox, and p67phox are predominantly expressed in mesangial cells, podocytes 
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express mainly Nox1, 4 and 5, and p22phox [170, 171, 177-181], while Nox1, 2, 4 and 5 and 
p47phox have been identified in glomerular endothelial cells [78, 169, 179, 182]; Nox5 is also 
expressed in proximal tubular cells, with Nox4 and Nox1 distributed in the whole tubular 
compartment [169, 171](Table 2). 
The role of NADPH oxidase is very important in both the physiological and disease setting where it 
drives oxidant species production as signalling molecules or oxidative-stress mediated cellular 
damage respectively [183]. NADPH oxidase is activated by various stimuli such as cellular ligands 
like growth factors (e.g. epidermal growth factor and TGF-β1), cytokines (e.g. tumour necrosis 
factor-α), and G protein-coupled receptor agonists (e.g. angiotensin-II, endothelin-1), and physical 
stimuli (e.g. high glucose, advance glycation product, lipids, mechanical stretch, shear stress)[184-
187]. 
Nox2, highly expressed in lymphomonocytes, may play an important role in inflammatory 
processes [188], key in the pathophysiology of DN. 
 
Mitochondrial oxidative stress: 
One of the major determinants of cellular oxidative stress in renal cells is the excess in cellular 
glucose uptake. This is driven by the interaction of ambient elevated circulating glucose and the 
haemodynamic perturbations at the glomerular capillary level, resulting in upregulation of basal 
glucose transport [17, 39]. 
Once transported into the cells, glucose undergoes glycolysis to form pyruvate, which is further 
metabolised in the Krebs cycle to generate nicotinamide (NADH) and flavin adenine dinucleotide 
(FADH2). These molecules participate as electron donors during oxidative phosphorylation and, in 
mitochondria, generate adenosine triphosphate (ATP). In conditions of hyperglycaemia (high 
glucose) and/or mitochondrial dysfunction, the mitochondrial ability to transport electrons is 
overcome with a subsequent increase in superoxide production [28, 189, 190]. 
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The accumulation of free radicals results in DNA alterations/damage that occurs mainly at the 
level of mitochondrial deoxyribonucleic acid (DNA), which is deficient in histones and therefore 
more susceptible to damage. Mitochondrial DNA damage, in turns, leads to further alteration on 
the respiratory chain resulting in further accumulation of free radicals. 
 
eNOS uncoupling 
Nitric oxide synthase (NOS) is expressed, in dimeric form, in most renal cells where all its three 
major isoforms are represented: inducible NOS (iNOS), neuronal NOS (nNOS) and endothelial NOS 
(eNOS)[191, 192]. eNOS has been implicated in superoxide production in diabetes when metabolic 
and haemodynamic perturbations alter the eNOS ability to generate nitric oxide (NO). In diabetes 
eNOS functionality is affected by the availability of its major substrate L-Arginine and cofactors 
such as tetrahydrobiopterin (BH4)[193]. BH4 is an important mediator of eNOS regulation in 
diabetes [194], and its reduced availability results in endothelial eNOS uncoupling from its major 
substrate L-Arginine resulting in inhibition of eNOS-mediated NO formation, with eNOS acquiring 
the ability to form superoxide and contributing to oxidant species imbalance [195, 196]. 
Specifically, Satoh et al have documented the uncoupling of eNOS as an additional source of 
superoxide in isolated glomerular tissues from streptozotocin-induced diabetic rats; restoration of 
physiological BH4 concentration was associated with diminished oxidant species generation and 
improved renal function [197]. These findings support the earlier work in which inhibition of eNOS 
using L-nitro-arginine methyl ester (L-NAME) prevented renal tissue injury in diabetes [198]. 
 
Xanthine oxidase pathway 
Xanthine oxidase and xanthine dehydrogenase expression depends closely on cellular content of 
hydrogen peroxide (e.g. in diseased tissue)[199] and are mainly expressed in epithelial cells. 
Xanthine oxidase utilizes hypoxanthine or xanthine as a substrate and oxygen as an electron 
acceptor to generate superoxide and uric acid. In experimental model of diabetes, xanthine 
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oxidase is abnormally active in kidneys of diabetic rats and has been linked to oxidative stress and 
the pathophysiology of diabetic nephropathy [200]. Xanthine oxidase is also involved in the 
synthesis of uric acid, which in turn has a recognised role in diabetic nephropathy [201, 202]; 
indeed uric acid favours excess production of oxidative stress, drives inflammatory processes and 
promotes cell death [203]. Uric acid levels have been shown to correlate with cardiovascular and 
kidney disease [204]. 
 
Cyclooxygenase pathway 
The cyclooxygenase pathway is important in arachidonic acid metabolism, and is highly expressed 
in the kidney [205]. Arachidonic acid derives from the cleavage of membrane phospholipids by 
phospholipase A2 which produces the major substrate for cyclooxygenase (COX) in the synthesis 
of prostaglandins G2 and, subsequently, prostaglandin H2. This is further metabolised by 
prostaglandin and thromboxane synthases to produce various prostaglandins and thromboxane 
A2, known to be important mediators of vascular tone and salt and water balance in the kidney. In 
mammals two major COX isoforms have been identified: the “constitutive” COX-1 and the 
inflammatory-mediated COX-2 isoform [205]. COX-1 is expressed in both the glomerular and 
tubular compartment while COX-2 is mainly expressed at the level of macula densa [206, 207]. 
COX-2 is a source of free radicals [208] and its increased activity associates with increased oxidant 
species production and apoptosis in renal cells in culture [209, 210]. Products of COX-2 such as 
thromboxane and PGE2 can induce, via the prostaglandin EP1 receptor, NADPH oxidase activity 
[211, 212] and in turn, oxidant species can induce COX-2 expression [213]. Conversely, PGE2 acting 
via the prostaglandin EP4 receptor can inhibit free radical production [214, 215]. 
COX-2 mediated oxidative stress reflects approximately 20-30% of total kidney oxidant species 
production, and it may play a more important role in ageing as its activity appears to increase with 
age, as observed in experimental animal models of diabetes. 
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The Brownlee hypothesis: an unifying theory (Fig. 4) 
The pathogenesis underlying diabetic complications has been originally hypothesised by Brownlee 
who presented a unifying theory in which increased oxidant species formation, as a result of 
chronic hyperglycaemia, is the single common upstream event driving a cascade of events that 
result in the development and progression of chronic vascular diabetic complications [30]. 
Prolonged exposure to high glucose levels induces DN [31] by modulating a variety of different 
signalling pathways [30]. Chronic hyperglycaemia increases mitochondrial oxidant species 
production, a central driving force in diabetic nephropathy pathogenesis and a significant factor 
contributing to accelerated cellular apoptosis [40, 216]. 
In normal physiological conditions electron transfer through complexes I, III, and IV, in the inner 
mitochondrial membrane, extrudes protons into the intermembrane space; the derived proton 
gradient drives the synthesis of ATP through complex V. Conversely, in diabetic condition 
characterised by elevated intracellular glucose concentration, more glucose is oxidised in the 
glycolytic and tricarboxylic acid cycle, causing an increase of electron donors, such as NADH and 
FADH2, into the electron transport chain that results in an increase in gradient across the inner 
mitochondrial membrane for ATP synthesis. When the gradient reaches a critical threshold, the 
transfer of electron at the level of complex III is blocked resulting in coenzyme Q to donate 
electrons to oxygen molecules, resulting in the generation of superoxide [28, 189, 217] which is 
then degraded by superoxide dismutase to hydrogen peroxide [218]. 
DNA damage by oxidant species leads to subsequent activation of poly-ADP-ribose polymerase 
(PARP), a DNA repair enzyme [219]. PARP activation results in the accumulation of ADP-ribose and 
secondary inhibition of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a key enzyme in the 
glycolytic process. 
Inhibition of GAPDH leads to the accumulation of precursors in the glycolytic cascade and 
secondary activation of the pentose, glucosamine, protein kinase C (PKC), and advance glycation 
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end products (AGE) methylglyoxal pathways, all of which are involved in the pathophysiology of 
DN [30]. Activation of the above mentioned metabolic pathways subsequently results in 
dysregulation of numerous cellular signalling molecules involved in inflammation (e.g. nuclear 
factor-kappa B (NF-kB)), cell response to insult (e.g. p38 mitogen-activated protein kinase (MAPK), 
Jun N-Terminal kinases [15]), and activators of ER stress and unfolded protein response. 
Conversely inhibition of mitochondrial reactive oxygen species has resulted in lack of glucose-
induced activation of PKC, formation of advanced glycation end-products, accumulation of sorbitol 
and activation of the transcription factor NFkβ [189]. 
 
The polyol pathway 
In normal physiology, a small percentage of glucose is metabolised through the polyol pathway as 
aldose reductase, a NADPH-dependent enzyme, has a low affinity for glucose. However, increased 
entry of glucose into cells in hyperglycaemic conditions results in more glucose entering the polyol 
pathway leading to secondary accumulation of sorbitol in cells, as excess glucose is converted to 
sorbitol by aldose reductase [30]. Increased sorbitol disrupts cellular osmolality and induces 
biochemical changes, such as NADP+ generation, which further contributes to increased oxidative 
stress and non-enzymatic glycation of proteins [216]. Moreover, further oxidation of sorbitol to 
fructose by the enzyme sorbitol dehydrogenase produces NADH which is believed to exacerbate 
the inhibition of GAPDH and simultaneously increase cellular levels of triose phosphate [220]. The 
detrimental consequences of increased activity of the polyol pathway are thought to be most 
closely associated with reduced concentrations of glutathione, secondary to increased NADPH 
consumption [221]. 
Ultimately, the definitive role of the polyol pathway in DN is still an area of debate where no 
definitive conclusions have been reached [40]. 
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Cellular formation of advanced glycation end products (AGEs) 
AGEs are a heterogeneous group of proteins, lipids and nucleic acids, cross-linked with reducing 
sugars that can determine the activation of cellular signalling proteins involved in increasing 
oxidative stress, inflammation and cytokine release [222]. Molecules generated from the auto-
oxidation of glucose and fructose, such as methylglyoxal, glyoxal and 3-deoxyglucosone, are 
known as AGE precursors [30, 223]. Thus, hyperglycaemia augments the production of AGEs and 
raised AGEs concentrations have been reported in the glomeruli of diabetic patients [224]. These 
molecules are involved in the pathogenesis of DN through multifactorial mechanisms, with 
evidence suggesting a significant role in diabetes-induced vascular injury [225, 226]. Intracellular 
protein dysfunction, abnormal extracellular matrix modification and AGE-receptor mediated 
oxidant species production are the three main mechanisms by which AGEs and their precursors 
lead to target cell damage [28]. AGE inhibitors have been found to partially reduce the 
development and progression of DN in experimental models of diabetes, thus highlighting the 
significance of AGEs in the pathogenesis of DN [227]. 
 
The protein kinase C pathway 
The PKC family is formed of 11 isoforms, a majority of which are activated by diacylglycerol (DAG), 
a second messenger found in elevated concentrations in hyperglycaemic intracellular 
environments [228]. DAG is increased in the diabetic glomeruli and many studies have confirmed 
the link between hyperglycaemia, direct activation of the diacylglycerol-protein kinase C (DAG-
PKC) and the development of cardio-renal vascular disease [229]. Indirect activation of the PKC 
pathway in hyperglycaemia, through increased polyol pathway and increased AGEs, has also been 
proposed [230]. Increased PKC activation (mainly of the β and δ isoforms) can lead to disruptions 
and altered expression of many intercellular proteins, namely eNOS, endothelin-1, vascular 
endothelial growth factor and TFG-β1 [216]. The effects of this vary from basement membrane 
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thickening, to vascular permeability alterations to pro-inflammatory gene expression. Specific β-
isoform PKC inhibitors have been shown to counter enhanced mesangial expansion in the 
glomerulus [231]. Of interest, other isoforms such us PKC-α and PKC-ε have been proposed as 
protective in the pathophysiology of DN [232]. 
 
The hexosamine pathway 
Hyperglycaemic conditions cause excess glucose to be shunted into the hexosamine metabolic 
pathway, which presents an additional pathway leading to the manifestations of diabetic 
complications [233]. An increase in activity of this pathway causes increased levels of fructose-6-
phosphate with subsequently elevated expression of TGF-α, TGF-β1 and plasminogen activator 
inhibitor 1 (PAI-1)[217, 233]. This has negative effects leading to increased extracellular matrix 
expression and accumulation at the tissue level [30]. 
 
Novel perspectives on oxidant species in diabetic nephropathy: mitochondrial hormesis 
The hypothesis that oxidant species are a major driver in the pathophysiology of chronic diabetic 
vascular complications and DN, depicted by Brownlee, has been challenged by negative results 
obtained in antioxidant-based clinical trials [40]. 
Following these observations, a new theory of “mitochondrial hormesis” has been proposed [234]: 
mitochondrial hormesis describes the concept that oxidant species, not only causes oxidative 
stress if elevated, but may function, at physiological concentration, as signalling molecules that 
promote health; therefore mitochondrial superoxide production could be considered as an 
indicator of healthy mitochondria and physiologic oxidative phosphorylation. 
Research in experimental animal models of diabetes (STZ-induced diabetic Akita-mice) has 
demonstrated a reduction in the levels of renal mitochondrial superoxide, secondary to diabetes-
mediated alteration of mitochondrial respiration [124]. Based on these findings, genetic or 
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pharmacological correction of mitochondrial respiration should confer a degree of renoprotection 
in mouse models of tubulointerstitial fibrosis [235]. 
Studies have highlighted the need for a more targeted antioxidant approach towards specific cell 
compartments as, in addition to mitochondrial oxidant species production, cytosolic and other 
non-mitochondrial sources of oxidant species may also play a role in the pathophysiology of DN 
[236]. Moreover, studies in humans have demonstrated that leukocytes, from patients with 
diabetes and DN, have a reduced maximal respiration and reserve capacity (when compared to 
non-diabetic controls) suggesting that the diabetic environment does manifest with alteration in 
ATP-linked respiration, low reserve capacity and mitochondrial damage [237, 238]. 
The Brownlee [28] and “mitochondrial hormesis” [234] hypotheses, apparently in contrast, could 
represent the same phenomena but at different stages of disease progression. One could 
speculate that in the initial phase of diabetes, the hyperglycaemic/haemodynamic insult to the 
kidney drives excess oxidant species production. This may gradually lead to secondary impairment 
of the mitochondria cellular respiratory machinery and consequently, result in altered respiration 
with reduction in pyruvate oxidation, reduced oxidant species production and cell death. The 
reduction in pyruvate oxidation in tricarboxylic acid cycle has been attributed to an increase in 
pyruvate dehydrogenase phosphorylation (as found in diabetic kidney)[124], known to inhibit 
pyruvate uptake into mitochondria. Of interest a recent report suggests that activation of 
pyruvate kinase M2, improves mitochondrial dysfunction by increasing mitochondrial metabolism 
and mitochondrial mass [239]. 
The safeguarding of an adequate number of healthy mitochondria in disease seems to be critical 
for both cell survival and for the preservation of a “balanced” level of cellular oxidant species (Fig. 
5). 
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Therapeutic strategies in diabetic nephropathy 
Current treatment strategies 
The central concept in treating diabetic complications is prevention of its known risk factors and 
this has largely been influenced by findings from major landmark clinical trials. The Diabetes 
Control and Complications Trial (DCCT) demonstrated that intensive glycaemic control in T1DM 
had major benefits in preventing GFR decline [31] and the development and progression of 
proteinuria [22]. Furthermore, these patients experienced a long lasting reduction of 
approximately 40% in the risk for the development of micro-albuminuria, for up to 7-8 years after 
the trial [240]. 
In patients with T2DM, the United Kingdom Prospective Diabetes Study (UKPDS) found a 30% 
reduction in the incidence of micro-albuminuria for the intensively treated group with better 
diabetes control [241]. Furthermore, the UKPDS also identified that a reduction of systolic blood 
pressure reduced the development of micro-albuminuria by 29% [242]. Blockers of the RAAS have 
been shown to slow down the progression to ESRD, independently of their antihypertensive 
effect; RAAS blockade significantly attenuates oxidant species production through the inhibition of 
angiotensin II-mediated NADPH oxidase activation. However, complete oxidant species production 
suppression is not completely achieved and alternative sources of oxidant species, such as the 
mitochondria, might still play a role in DN progression [243]. 
 
The role of antioxidant therapy: results from clinical trials 
Given the prominent role of oxidant species in the development of diabetic nephropathy, anti-
oxidant therapies have been tested as a promising and exciting avenue of investigation and 
research in the progression of diabetic kidney disease and other chronic diabetic complications. 
Theoretically, the ideal anti-oxidant therapy would be specific, have minimal side effects and 
effectively target all identified oxidant species pathways. 
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To date many trials have been conducted but the clinical observations in humans have not 
matched the promising observations obtained in pre-clinical animal models [244]. 
In studies in patients with diabetes, administration of Vitamin E, an antioxidant acting as a peroxyl 
radical scavenger, failed to show beneficial effect on vascular chronic complications [245]; further 
antioxidant supplementation has not shown any definitive benefit on endothelial dysfunction and 
specifically, on renal outcomes [246, 247]. 
Conversely some studies investigating vitamin E oral administration normalized hyperfiltration in 
patients with type 1 diabetes [248], and antioxidant combination therapies of vitamins E and C 
seems to confer some degree of renoprotection in patients with type 2 diabetes, though results 
are not conclusive [247]. Benfotiamine, a synthetic S-acyl derivative of thiamine (vitamin B1) with 
antioxidant properties, has been shown to reduce albuminuria in patients with type 2 diabetes 
[249]. 
More recently bardoxolone-methyl, an activator of the antioxidant transcription factor Nrf2 with 
reported antioxidant and anti-inflammatory properties, resulted in increased albuminuria 
paralleled by hyperfiltration and increased risk of death in patients with advanced renal disease 
[250]. Promising results have recently emerged in experimental animal models of diabetes 
investigating the effectiveness of a novel analogue of the Nrf2 agonist bardoxolone methyl [251]. 
Three months administration of silymarin, a unique flavonoid complex derived from the milk 
thistle plant with antioxidant and anti-inflammatory properties, was paralleled with a reduction in 
urinary excretion of albumin, TNF-α, and malondialdehyde in patients with diabetic nephropathy 
[252]. 
From these series of studies, it seems that most attempt in reducing oxidative stress in humans 
with dietary antioxidant therapy do not translate in organ protection; the reasons might be 
different. 
Oxidative stress may not be only process involved in the pathogenesis of a disease. As an example, 
in DN, pathophysiological processes such as inflammation, activation of apoptotic pathways might 
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be partly unrelated to the increase in oxidant species, and therefore might not be completely 
targeted by antioxidant therapy. Bioavailability could also be an issue: many of the compounds 
utilised are susceptible to auto-oxidation in the gut, have limited absorption and can be rapidly 
metabolised by the gut microbiota reducing their bioavailability [253, 254]; in this respect, there 
might be a patient susceptibility for a response to antioxidant therapy. Future work might have to 
consider different, more stable formulation of antioxidants to plan new clinical research trials. 
 
Novel therapeutic approaches 
There has been growing interest in targeting uric acid as an antioxidant treatment for diabetic 
nephropathy and current ongoing trials in humans are testing the role of allopurinol as a 
nephroprotective agent in patients with T1DM [255]. 
The NOX1/NOX4 inhibitor GKT137831 (Genkyotex) showed considerable promise in its phase-I 
trial, but failed to reduce albuminuria in patients with diabetes and kidney disease 
(https://www.genkyotex.com/en/pipeline/gkt831); further studies are on the way to dissect the 
potential positioning of this molecule in clinical medicine. 
Pentoxifylline, a methylxanthine derivate and nonspecific phosphodiesterase inhibitor clinically 
used to treat patients with occlusive peripheral vascular disorders, which retains anti-
inflammatory, anti-fibrotic anti-oxidant properties [256] has revealed a renoprotective role in 
patients with diabetes. Additional studies are needed to confirm these promising results in larger 
clinical trials [257]. 
 
Concluding remarks and future perspectives 
We believe that there is strong experimental evidence that oxidative stress is involved in the 
pathophysiology of DN. The overall failure of clinical trials using antioxidant for the treatment of 
DN should be carefully assessed before coming to definitive conclusions.  
 28 
We will need to understand better the role of oxidative stress in either physiology and disease 
before we can securely test novel antioxidant treatments. Key understanding to be answered in 
future studies is the role of specific oxidant species within each cellular compartment both in 
physiology and disease conditions; further there is building evidence that oxidant species have a 
clear role in cell signaling [258], and therefore putative treatments targeting excess oxidant 
species will have to “modulate” rather than inhibit cellular oxidative status. 
The role of oxidant species as pro-oxidant and/or activators/inhibitors of cellular signalling 
pathways is likely to be different in different diseases setting (e.g. acute versus chronic) and could 
also change as diseases progress and evolve with time. 
Careful understanding of the mechanisms of any new molecule able to modulate cellular oxidative 
stress will have to be a prerequisite for its translation in the clinical setting. The altered dynamics 
of oxidant species in cells and tissues in diseases, makes the search for new antioxidant therapy 
challenging. Challenges often bring new discoveries; hopefully research targeting antioxidant 
specific interventions to ameliorate DN or disease in general will be translated to humans in the 
next few years. 
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Figures: 
Fig. 1: Metabolic-haemodynamic interaction in DN: Schematic representation of interaction 
between metabolic and haemodynamic factors contributing to diabetic nephropathy. 
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Fig. 2: Structural schematic of normal and diabetic glomerulus. Normal (left) and diabetic (right) 
glomeruli. The diabetic glomeruli is characterised by podocyte apoptosis and detachment, thickening 
of the GBM, endothelial cell apoptosis, and mesangial expansion). 
 
 
Fig. 3: Sources of oxidative stress in diabetes. NADPH: nicotinamide adenine dinucleotide 
phosphate; eNOS: endothelial nitric oxide synthase; COX: cyclooxygenase. 
 
Fig. 4: Pathophysiology of diabetic nephropathy. Schematic overview of the signalling cascade 
induced by hyperglycaemia-mediated activation of the four key pathways underlying the 
pathogenesis of diabetic nephropathy; the polyol pathway, the advanced glycation end products 
pathway, the hexosamine pathway and the protein kinase C pathway. (PARP - poly-ADP-ribose 
polymerase; GAPDH - glyceraldehyde phosphate dehydrogenase; MAPK - mitogen activated protein 
kinase). 
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Fig. 5: Mitochondrial dysfunction in diabetes. Excess glucose entry in the cell will initially determine 
an increase oxidative stress (left image); this scenario might change in later stages of the disease 
characterised by mainly mitochondrial dysfunction and cell death, a scenario paralleled by a 
reduction in free radical production by mitochondria (right image) (TCA: tricarboxylic acid; ETC: 
electron transport chain; O2-: superoxide). 
 
 
Tables: 
 
Table 1: Stages of diabetic nephropathy 
Stage of Diabetic Nephropathy Description 
Stage 1: Glomerular 
Hyperfiltration 
Early hyperfunction and hypertrophy 
Stage 2: Silent Stage Glomerular lesions without clinical disease 
Stage 3: Incipient Nephropathy 
with Microalbuminuria 
Urine albumin excretion (UAE) 30-300mg/day 
Stage 4: Overt Nephropathy Urine albumin excretion (UAE) >300mg/day 
Stage 5: End-Stage Renal 
Disease 
Major loss of kidney function, requires dialysis 
 
Table 2: Distribution of NADPH oxidase subunits in renal cells 
Anatomical site NADPH component References 
Renal cortex Nox1, Nox2, Nox4 p22
phox
, p47
phox
, p67
phox
 [176] 
Renal vessels Nox-2, p22
phox
 [182] 
Microvascular glomerular 
endothelial cells 
Nox1, Nox2, Nox4, Nox5, p47
phox
 [78, 169, 179, 
182] 
Glomeruli Nox1, Nox 2, Nox4, Nox5, p22
phox
, p47
phox
, 
p67
phox
, 
[177, 259, 260] 
[78, 169, 179, 
182] 
Mesangial cells Nox1, Nox2, Nox4, p22
phox
, p47
phox
, p67
phox
 [170, 173, 261] 
 48 
Podocytes Nox1, Nox4, Nox5, p22
phox
, p47
phox
, p67
phox
 [170, 171, 177-
181] 
Interstitial fibroblast p22
phox
 [177] 
Proximal tubule Nox5, p22
phox
 [169, 171, 262] 
Thick ascending limb Nox1, Nox4, Nox2, p40
phox
, p22
phox
, p47
phox
, 
p67
phox
 
[169, 179, 263] 
Macula densa p22
phox
, p47
phox
, p67
phox
 [179] 
Distal convolute tubule Nox1, Nox4, p22
phox
, p47
phox
, p67
phox
 [169, 179] 
Cortical collecting duct Nox1, Nox4, p22
phox
, p47
phox
, p67
phox
 [169, 179] 
Medullary collecting duct Nox1, Nox4, p22
phox
, p47
phox
, p67
phox
 [169, 179] 
 
 
Highlights 
 Experimental models suggest an important role for oxidative stress in the pathophysiology 
of diabetic nephropathy. 
 Clinical trials with antioxidant therapy have not delivered convincing results. 
 Free radicals are important in cell physiology and treatments targeting oxidative stress in 
disease conditions should consider that complete inhibition of reactive oxygen species 
formation is not beneficial. 
 Targeting oxidative stress may require different strategies in different phases (early, 
advanced) of chronic diseases. 
 
 
